

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA: Pembrolizumab with axitinib for untreated locally advanced or metastatic renal cell carcinoma ID1426

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A potential equality issue was identified during the draft scope consultation:

Access to treatment: Administration of pembrolizumab plus axitinib requires hospital visits every 3 weeks and the use of a chemotherapy chair for the infusion. Travel to/from the hospital, accommodation costs for people in remote areas, time off work for hospital appointments etc. could exclude patients living in remote areas or patients from poor socioeconomic backgrounds from receiving treatment.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This does not relate to any groups protected by the legislation - committee's decision relates equally to all people in England. Equality of access across England and socio-economic groups is not an equality issue to be addressed by committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Not applicable.

Approved by Associate Director (name): Frances Sutcliffe

Date: 09/08/2018